PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

ICRAKI: Initial Intermittent Dialysis Linked to Higher Mortality Than Continuous Therapy

★ Editor's Pickintermittent hemodialysiscontinuous renal-replacement therapyCRRTacute kidney injurycritical carerenal pharmacyrandomized controlled trialnoninferioritymortalitymajor adverse kidney eventsICU Nephrology / Renal Pharmacy

Background Information

Continuous therapy might reduce mortality in critically ill kidney injury patients.

Renal-replacement therapy choice impacts outcomes in acute kidney injury management for critically ill patients. Intermittent hemodialysis showed higher mortality (63.1%) compared to continuous therapy (53.5%) for major adverse kidney events by day 90. Continuous renal-replacement therapy may reduce mortality compared to intermittent hemodialysis in critically ill acute kidney injury patients. Continuous renal-replacement therapy may be preferred over intermittent hemodialysis in acute kidney injury for better survival outcomes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Gaudry S, Boubaya M, Louis G, Chaïbi K, de Montmollin E, Bohé J, Desgrouas M, Devautour C, Joseph A, Mégarbane B, Camus C, Bailly P, Lambour A, Arrestier R, Jaber S, Robine A, Chudeau N, Chevrel G, La Combe B, Nicolas J, Argaud L, Bureau C, Kimmoun A, Zucman N, Ricard JD, Thiery G, Faguer S, Jozwiak M, Ferrand N, Chousterman B, Marzouk M, Cadiet J, Combes A, Mari A, Contou D, Amathieu R, Da Silva D, Gandonnière CS, Rodie-Talbere PA, Durand-Zaleski I, Rossignol P, Quenot JP, Biard L, Bloch C, Dreyfuss D, ICRAKI Trial Group

Citation: Gaudry S, Boubaya M, Louis G, et al. Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury. The New England journal of medicine. 2026;395(17):1677-1690. doi:10.1056/NEJMoa2608397

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.